SGP SpyGlass Pharma (SGP) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001778922
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
40
13F, latest reported quarter
SGP filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by RA Capital Management, L.P., filed 2026-02-17, for 24.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
SpyGlass Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SpyGlass Pharma, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.1% of the 2,054,678 shares held after it.
- 14 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA Capital Healthcare Fund LP bought about $4.0M of SGP on Feb 9, 2026, the largest insider purchase at the company on our record; 14 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 57.7% of the 5,966,439 shares held after it.
- 14 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA Capital Healthcare Fund LP bought about $55.1M of SGP on Feb 9, 2026, the largest insider purchase at the company on our record; 14 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 15.5% of the 6,035,038 shares held after it.
- 14 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Behbahani Ali bought about $15.0M of SGP on Feb 9, 2026, the largest insider purchase at the company on our record; 14 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 15.5% of the 6,035,038 shares held after it.
- 14 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Florence Anthony A. Jr. bought about $15.0M of SGP on Feb 9, 2026, the largest insider purchase at the company on our record; 14 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 15.5% of the 6,035,038 shares held after it.
- 14 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider BASKETT FOREST bought about $15.0M of SGP on Feb 9, 2026, the largest insider purchase at the company on our record; 14 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
40 funds bought in last quarter
below 63% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$1.4M repurchased, FY to 2025-12-31
below 85% of Medical Devices
Short interest
19.3% of the float short (float per yahoo 2026-10-26) · 7.1 days to cover · settled 2026-09-30
more than 53% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SGP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.3%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SGP: institutional holders (13F)
13F holdings, latest reported quarter
8,021,117 sh
$178.6M
7,392,301 sh
$164.6M
2,500,012 sh
$55.7M
2,109,953 sh
$47.0M
711,712 sh
$15.8M
Congress trades in SGP
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
RA Capital Management, L.P.
Activist 13D · 2026-02-17
24.1%
Peter Kolchinsky
Activist 13D · 2026-02-17
24.1%
Rajeev Shah
Activist 13D · 2026-02-17
24.1%
RA Capital Healthcare Fund, L.P.
Activist 13D · 2026-02-17
17.9%
RA Capital Nexus Fund III, L.P.
Activist 13D · 2026-02-17
6.2%
SGP planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SGP mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$379.7K position · as of 2026-07-31
0.8%
JPMorgan Small Cap Growth Fund
$6.5M position · as of 2026-06-30
0.2%
Franklin Biotechnology Discovery Fund
$1.9M position · as of 2026-07-31
0.2%
JPMorgan Small Cap Blend Fund
$2.1M position · as of 2026-06-30
0.1%
Multi-Manager Small Cap Equity Strategies Fund
$889.1K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$826.6K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 3
2 active
2
Not applicable
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 40 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SGP financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | |
|---|---|---|
| Operating income | -$41.4M | -$27.1M |
| Net income | -$39.9M | -$29.2M |
| EPS (diluted) | -17.98 | -16.31 |
| Operating cash flow | -$32.7M | -$22.0M |
| Cash | $96.4M | $16.3M |
| Buybacks | $1.4M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
SGP Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
